These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33757805)

  • 1. Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world.
    Crespo J; Lazarus JV; Iruzubieta P; García F; García-Samaniego J;
    J Hepatol; 2021 Jul; 75(1):224-226. PubMed ID: 33757805
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno.
    Torre P; Annunziata M; Sciorio R; Coppola C; Masarone M; Persico M
    Liver Int; 2022 Jun; 42(6):1467-1469. PubMed ID: 35395130
    [No Abstract]   [Full Text] [Related]  

  • 3. Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study.
    Coppola C; Masarone M; Bartoli M; Staiano L; Coppola R; Torre P; Conforti M; Amoruso D; Gardini I; Persico M
    J Viral Hepat; 2022 Feb; 29(2):171-173. PubMed ID: 34585821
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    do Carmo RF; de Souza CDF
    J Hepatol; 2022 Feb; 76(2):470-472. PubMed ID: 34437907
    [No Abstract]   [Full Text] [Related]  

  • 5. HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    Crespo J; Díaz-González Á; Cabezas J
    J Hepatol; 2021 Aug; 75(2):486-487. PubMed ID: 33971225
    [No Abstract]   [Full Text] [Related]  

  • 6. Is elimination of HCV in 2030 realistic in Central Europe.
    Flisiak R; Zarębska-Michaluk D; Frankova S; Grgurevic I; Hunyady B; Jarcuska P; Kupčinskas L; Makara M; Simonova M; Sperl J; Tolmane I; Vince A
    Liver Int; 2021 Jun; 41 Suppl 1():56-60. PubMed ID: 34155796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus micro-elimination: Where do we stand?
    Mangia A; Cotugno R; Cocomazzi G; Squillante MM; Piazzolla V
    World J Gastroenterol; 2021 Apr; 27(16):1728-1737. PubMed ID: 33967553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the COVID-19 pandemic on HCV elimination in Spain.
    Buti M; Domínguez-Hernández R; Casado MA
    J Hepatol; 2021 May; 74(5):1246-1248. PubMed ID: 33358780
    [No Abstract]   [Full Text] [Related]  

  • 9. Detecting HCV infection by means of mass population SARS-CoV-2 screening: A pilot experience in Northern Italy.
    Giacomelli A; Pagani G; Conti F; Bassoli C; Galli M
    J Hepatol; 2021 Aug; 75(2):484-486. PubMed ID: 33453329
    [No Abstract]   [Full Text] [Related]  

  • 10. BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.
    Queiroz NSF; Teixeira FV; Freire CCF; Motta MP; Vasconcellos MAM; Chebli LA; Saad-Hossne R;
    Arq Gastroenterol; 2021; 58(1):1-4. PubMed ID: 33909805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination.
    Crespo J; Díaz-González Á; Iruzubieta P; Llerena S; Cabezas J
    J Hepatol; 2021 Apr; 74(4):966-967. PubMed ID: 33039405
    [No Abstract]   [Full Text] [Related]  

  • 12. The SARS-CoV2 pandemic and routine immunisation.
    Kang G
    Lancet Glob Health; 2022 Feb; 10(2):e155-e156. PubMed ID: 35063102
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunity against SARS-CoV-2: walking to the vaccination].
    Rodríguez Hernández C; Sanz Moreno L
    Rev Esp Quimioter; 2020 Dec; 33(6):392-398. PubMed ID: 32935536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covid vaccination in patients with autoimmune diseases treated with mycophenolate: Let's think back to the recommendations.
    Benucci M; Infantino M; Manfredi M; Li Gobbi F; Sarzi-Puttini P; Caproni M
    Autoimmun Rev; 2021 Oct; 20(10):102908. PubMed ID: 34274547
    [No Abstract]   [Full Text] [Related]  

  • 15. HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy.
    Beltrami M; Pagani G; Conti F; Pezzati L; Casalini G; Rondanin R; Prina A; Zagari A; Galli M; Giacomelli A
    Liver Int; 2023 Jan; 43(1):251-255. PubMed ID: 35869660
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection.
    Taubner B; Peredo-Wende R; Ramani A; Singh G; Strle K; Cady NC
    Microbiol Spectr; 2021 Oct; 9(2):e0089021. PubMed ID: 34585942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Founder Effect Led Early SARS-CoV-2 Transmission in Spain.
    Díez-Fuertes F; Iglesias-Caballero M; García-Pérez J; Monzón S; Jiménez P; Varona S; Cuesta I; Zaballos Á; Jiménez M; Checa L; Pozo F; Pérez-Olmeda M; Thomson MM; Alcamí J; Casas I
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33127745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination.
    Mumoli L; Vescio V; Pirritano D; Russo E; Bosco D
    Neurol Sci; 2022 Feb; 43(2):763-766. PubMed ID: 34796418
    [No Abstract]   [Full Text] [Related]  

  • 19. Parsonage-turner syndrome associated with SARS-CoV2 (COVID-19) infection.
    Mitry MA; Collins LK; Kazam JJ; Kaicker S; Kovanlikaya A
    Clin Imaging; 2021 Apr; 72():8-10. PubMed ID: 33190028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19.
    Chimoyi L; Velen K; Churchyard GJ; Wallis R; Lewis JJ; Charalambous S
    PLoS One; 2020; 15(12):e0243707. PubMed ID: 33332418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.